Abstract
For most researchers, discovering new anticancer drugs to avoid the adverse effects of current ones, to improve therapeutic benefits and to reduce resistance is essential. Because the COX-2 enzyme plays an important role in various types of cancer leading to malignancy enhancement, inhibition of apoptosis, and tumor-cell metastasis, an indispensable objective is to design new scaffolds or drugs that possess combined action or dual effect, such as kinase and COX-2 inhibition. The start compounds A1 to A6 were prepared through the diazo coupling of 3-aminoacetophenone with a corresponding phenol and then condensed with two new chalcone series, C7–18. The newly synthesized compounds were assessed against both COX-2 and epidermal growth factor receptor (EGFR) for their inhibitory effect. All novel compounds were screened for cytotoxicity against five cancer cell lines. Compounds C9 and G10 exhibited potent EGFR inhibition with IC50 values of 0.8 and 1.1 µM, respectively. Additionally, they also displayed great COX-2 inhibition with IC50 values of 1.27 and 1.88 µM, respectively. Furthermore, the target compounds were assessed for their cytotoxicity against pancreatic ductal cancer (Panc-1), lung cancer (H-460), human colon cancer (HT-29), human malignant melanoma (A375) and pancreatic cancer (PaCa-2) cell lines. Interestingly, compounds C10 and G12 exhibited the strongest cytotoxic effect against PaCa-2 with average IC50 values of 0.9 and 0.8 µM, respectively. To understand the possible binding modes of the compounds under investigation with the receptor cites of EGFR and COX-2, a virtual docking study was conducted.
Highlights
Cancer is the second-highest cause of death in the United States and a serious public health concern globally
The main target of this research was the design of multi-target drugs oriented towards two critical enzymes COX-2 and epidermal growth factor receptor (EGFR)
A future plan for this work concerns in vivo studies for inflammation and cancer and a study of the toxicity of synthesized compounds
Summary
Cancer is the second-highest cause of death in the United States and a serious public health concern globally. Several studies have revealed that EGFR and COX-2 signaling pathways work together to promote cancer. EGFR is a tyrosine kinase (TK) receptor that is activated when it is bound to the Epidermal Growth Factor and other growth factor ligands This activates a number of downstream pathways that control cell processes such as DNA synthesis and proliferation [10,11]. It has become a major target for various cancer therapies. New and more effective chemotherapeutics that target multiple cancerrelated pathways at the same time by using multi-target drugs could be developed [13] Development of such drugs to act as both kinase and COX inhibitors is predicted to be very effective and selective in treating cancer [14–19]. The aim of Ftihguisres1t. uStdruyctuirse otforedpoersteidgcnomaponuenwds (Asc, BafafnodlCd) acnodntatrgaeitncoinmgpoucnhdas l(cCo7–n18e) with promising anticancer effect throTuhegthargthetecoimnphoiubnidtisowneroe fprkepinaraesdeacacnorddinCgOtoXtheefnozlloywminegssc(hSecmhees.mes 1–3 and Figure 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
